Pathstone Holdings
CRSP icon

Pathstone Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Pathstone Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,293
Closed -$213K – 2268
2025
Q3 		$213K Buy
+3,293
New +$189K ﹤0.01% 2179
2024
Q2 		– Sell
-3,126
Closed -$213K – 2323
2024
Q1 		$213K Buy
+3,126
New +$224K ﹤0.01% 2110

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's CRSP Position: Q4 2025 in Review

Pathstone Holdings sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,293 shares — an estimated $213K sold.

Pathstone Holdings first reported a position in CRSP in Q1 2024 and held it in 2 quarters. The position peaked at $213K in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Pathstone Holdings reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Pathstone Holdings sold 3,293 CRISPR Therapeutics shares in Q4 2025, an estimated $213K.
  • Pathstone Holdings first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 2 quarters.
  • Pathstone Holdings's CRISPR Therapeutics position peaked at $213K in Q3 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Pathstone Holdings's 13F filing for Q4 2025, filed 13 Feb 2026.